Final analysis of TUXEDO-1 for HER2+ MBC
Kathrin Dvir, Chief Fellow Hematology-Oncology at Dana-Farber Cancer Institute, shared a post by Paolo Tarantino, on X:
“Brain metastasis is a HUGE unmet need, esp in HER2+. As reference, in exploratory analyses of intracranial efficacy of HER2Climb mCNS-PFS was 9.9 months and that included both active and treated BMs. Larger trials are underway but T-DXd proves itself well against active brain mets.”
Quoting Paolo Tarantino‘s post:
“Final analysis of TUXEDO-1 published in SNO. Among 14 patients with active brain metastases from HER2+ MBC, treatment with T-DXd resulted in a median PFS of 21 months. Results from DB12 awaited to confirm these findings in a larger cohort.”
Authors: Rupert Bartsch, Anna Sophie Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Sophie Bergen, Sophie Roider-Schur, Maximilian Johannes Mair, Angelika Martina Starzer, Heidrun Forstner, Beate Rottenmanner, Marie-Bernadette Aretin, Karin Dieckmann, Zsuzsanna Bago-Horvath, Helmuth Haslacher, Georg Widhalm, Aysegül Ilhan-Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, Thomas Szekeres, Leopold Oehler, Birgit Gruenberger, Georg Pfeiler, Christian Singer, Ansgar Weltermann, Luzia Berchtold, Matthias Preusser.
Source: Kathrin Dvir/X and Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.